https://perksignal.com/index.p....hp/investigation-ass
Pancreatic cyst aspirate evaluations benefit from the application of PancreaSeq, as demonstrated in this study. Our institution began offering PancreaSeq testing on June 1st, 2022. Cytological testing was performed on 50 cyst aspirates collected between June 1, 2022, and December 31, 2022. The results revealed 26 (52%) as non-diagnostic, 4 (8%) as negativ
Like
Comment
Share
